Chemed Corporation beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging -0.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $5.12 | $5.52 | +7.8% | Beat | Q2 FY26 call |
| Q1 FY26 | $4.85 | $5.08 | +4.7% | Beat | |
| Q4 FY25 | $6.57 | $5.92 | -9.9% | Miss | Q4 FY25 call |
| Q3 FY25 | $4.94 | $4.94 | +0.0% | Beat | |
| Q2 FY25 | $4.27 | $3.75 | -12.2% | Miss | Q2 FY25 call |
| Q1 FY25 | $5.19 | $5.11 | -1.5% | Miss | |
| Q4 FY24 | $6.34 | $6.30 | -0.6% | Miss | |
| Q3 FY24 | $5.31 | $5.33 | +0.4% | Beat | |
| Q2 FY24 | $5.14 | $5.01 | -2.5% | Miss | |
| Q1 FY24 | $5.09 | $4.68 | -8.1% | Miss | |
| Q4 FY23 | $6.25 | $6.60 | +5.6% | Beat | |
| Q3 FY23 | $4.92 | $5.32 | +8.1% | Beat |
Back to CHE overview · CHE holders · CHE KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.